Screening Based on Structural and Biological Verification of Stachyose as a PPARγ‐Modulating Ligand for the Treatment of Non‐Alcoholic Fatty Liver Disease. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.